Promab: NantKwest : Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively�Develop Select Next Generation Targeted Natural Killer Cell Therapeutics

(marketscreener.com) Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate for Multiple Myeloma, with an Option for up to Five Additional CAR Targeting Sequences ...http://www.marketscreener.com/NANTKWEST-INC-23160241/news/NantKwest-Signs-Worldwide-License-Agreement-with-ProMab-Biotechnologies-to-Exclusively-Develop-Sel-28106177/?utm_medium=RSS&utm_content=20190304